E.Merge Technology Acquisition Corp. (NASDAQ: ETAC) announced this afternoon that it intends to dissolve and liquidate its trust due to its inability to complete a business combination.
The SPAC anticipates that the public shares will cease trading as of the close of business on September 4, 2022, and will redeem all of its outstanding shares from its IPO for approximately $10.06 per share.
E.Merge Technology, which priced an upsized IPO of $522 million over two years ago in July 2020, which grew to $600 million with its over-allotment, intended to find a target in the software and internet technology industries. The liquidation comes as a surprise as the SPAC’s sponsor recently contributed to its trust to extend its transaction timeline from August 4, 2022 to November 4, 2022.
ETAC marks the 18th SPAC liquidation so far in 2022, and the 5th in August thus far. The tech-focused SPAC was led by Jeff Clarke, as Co-Chief Executive Officer, Chief Financial Officer and Director, and Guy Gecht, as Co-Chief Executive Officer. S. Steven Singh will be Chairman of the Board of Directors.
Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...